Drug Rehab in California – Addiction Treatment at Highly Effective Rehab


 

Drug Rehab in California – Addiction Treatment at Highly Effective Rehab – www.SoberLiving.com Sober Living by the Sea is a drug rehab community that has been successfully treating alcoholism, drug addiction, and eating disorders for over 23 years right on the beach in beautiful Newport Beach, California. Visit http for more information. Our treatment center for addiction, alcoholism, and eating disorders offers individualized treatment planning that is personalized for the unique needs of any man or woman. Clients will be constantly engaged with therapeutic activities that are mixed in with esteem building outdoor activities right on the sands of Newport Beach in Orange County, CA. Sober Living by the Sea is is the premier resource for people who struggle with addiction to any substance. Some of our customized rograms include: – The Rose Exclusive Treatment for Women – The Landing Exclusive Treatment for Men – Sunrise Recovery Highly Structured Program in Riverside – The Victorian House for Eating Disorder Treatment – Long Term Rehab Options (Extended Care Program) – TEACH Sober College Program – Family Counseling and Rehab Treatment – Celebrate Recovery Christan Track – Transitional Work Program – Dual Diagnosis Treatment

 

Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients

Filed under: drug rehab treatment options

An experimental treatment for HIV developed by GlaxoSmithKline Plc (GSK), Pfizer Inc. (PFE) and Shionogi & Co. (4507) reduced the virus in hard-to-treat patients in a late-stage study, providing further support for a regulatory filing by the end of …
Read more on Businessweek

 

Is This Diabetes Drug Merck's Next Blockbuster?

Filed under: drug rehab treatment options

DPP-4 inhibitors are one of many types of treatments that act by regulating the body's insulin production in some way, making it harder to safely and successfully pair these drugs with insulin shots. But new SGLT-2 medications reroute glucose into the …
Read more on Motley Fool